Quantum BioPharma Ltd. (QNTM)
NASDAQ: QNTM · Real-Time Price · USD
3.120
-0.050 (-1.58%)
Apr 17, 2026, 4:00 PM EDT - Market closed
Quantum BioPharma Employees
Quantum BioPharma had 17 employees as of December 31, 2022. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
n/a
Profits / Employee
-$1,539,723
Market Cap
18.46M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2022 | 17 | 7 | 70.00% | 17 | 0 |
| Dec 31, 2021 | 10 | 1 | 11.11% | 10 | 0 |
| Dec 31, 2020 | 9 | -9 | -50.00% | 9 | 0 |
| Dec 31, 2019 | 18 | -1 | -5.26% | 17 | 1 |
| Sep 30, 2019 | 23 | 4 | 21.05% | 23 | 0 |
| Jun 30, 2019 | 19 | - | - | 19 | 0 |
| Dec 31, 2018 | 19 | - | - | 19 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Citius Pharmaceuticals | 23 |
| SeaStar Medical Holding | 17 |
| Lipocine | 14 |
| VYNE Therapeutics | 10 |
| Genenta Science | 9 |
| Allarity Therapeutics | 8 |
| Traws Pharma | 7 |
| Pasithea Therapeutics | 5 |
QNTM News
- 17 days ago - Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis - GlobeNewsWire
- 19 days ago - Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis - GlobeNewsWire
- 22 days ago - Quantum Biopharma Provides Corporate Update - GlobeNewsWire
- 22 days ago - Quantum Biopharma's 2025 Audited Year End Financial Results Maintain ‘No Going Concern' Status - GlobeNewsWire
- 26 days ago - Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd - GlobeNewsWire
- 4 weeks ago - Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering - GlobeNewsWire
- 5 weeks ago - Quantum BioPharma Provides Corporate Update - GlobeNewsWire
- 2 months ago - INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM - PRNewsWire